In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback